Smith & Nephew plc (LON:SN) had its price objective lowered by Goldman Sachs Group Inc. from GBX 1,370 ($17.12) to GBX 1,310 ($16.37) in a research report released on Friday. Goldman Sachs Group Inc. currently has a buy rating on the stock.

Other equities analysts have also issued reports about the stock. JPMorgan Chase & Co. lifted their target price on shares of Smith & Nephew plc from GBX 1,196 ($14.94) to GBX 1,199 ($14.98) and gave the company a neutral rating in a report on Friday, July 29th. BNP Paribas reaffirmed an outperform rating and set a GBX 1,425 ($17.80) target price on shares of Smith & Nephew plc in a report on Friday, July 29th. Barclays PLC lowered shares of Smith & Nephew plc to an equal weight rating and lifted their target price for the company from GBX 1,230 ($15.37) to GBX 1,240 ($15.49) in a report on Wednesday, August 10th. Beaufort Securities reaffirmed a hold rating on shares of Smith & Nephew plc in a report on Tuesday, August 9th. Finally, Credit Suisse Group AG reaffirmed a neutral rating and set a GBX 1,285 ($16.05) target price on shares of Smith & Nephew plc in a report on Friday, July 29th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of GBX 1,285.54 ($16.06).

Smith & Nephew plc (LON:SN) opened at 1115.6807 on Friday. The firm’s 50-day moving average is GBX 1,163.38 and its 200 day moving average is GBX 1,209.37. The company’s market cap is GBX 9.97 billion. Smith & Nephew plc has a 52-week low of GBX 1,040.36 and a 52-week high of GBX 1,324.00.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this report can be read at

About Smith & Nephew plc

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. The Company offers various product franchises, which include Knee implants, Hip implants, Sports Medicine Joint Repair, Arthroscopy Enabling Technologies, Trauma and Extremities, Other Surgical Businesses, Advanced Wound Care, Advanced Wound Devices and Advanced Wound Bioactives.

Receive News & Stock Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related stocks with our FREE daily email newsletter.